Feb 16, 2025 · DLL3 is an emerging therapeutic target in small cell lung cancer and other neuroendocrine carcinomas, with 1 FDA-approved therapy and several others under investigation.

Jun 24, 2023 · Delta-like ligand 3 (DLL3), a Notch inhibitory ligand, is an attractive therapeutic target because it is overexpressed on the surface of SCLC cells with minimal to no expression on normal cells.

May 20, 2019 · In this study, the expression of DLL3 was analyzed using different DLL3 antibodies in high-grade neuroendocrine tumors of the lung and cell cultures. Additionally, correlation of DLL3 expression with Rb1 loss and TP53 mutation was evaluated.

Here we investigated the atypical Notch ligand DLL3 as a biomarker of the neuroendocrine state and a regulator of cell-cell interactions in SCLC. We first built a mathematical model to predict the impact of DLL3 expression on SCLC cell populations.

Oct 20, 2023 · Tarlatamab is a bispecific T-cell engager immunotherapy that directs the patient’s T cells to cancer cells expressing delta-like ligand 3 (DLL3), independent of major histocompatibility complex...

May 10, 2024 · DLL3 acts as an inhibitory ligand that downregulates Notch signaling and is upregulated by ASCL1, a transcription factor prevalent in the small-cell lung cancer (SCLC) subtype SCLC-A. Currently, the therapeutic strategies targeting DLL3 are varied, including antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and chimeric ...

Jun 24, 2023 · In this review, we discuss various DLL3-targeting therapies starting with rovalpituzumab tesirine (Rova-T), the first DLL3-targeting antibody-drug conjugate (ADC), which advanced to phase 3 clinical studies before development was halted.

Aug 19, 2022 · Delta-like ligand 3 (DLL3) is overexpressed in many NENs, implicated in tumor progression, and associated with poor clinical outcomes, especially in patients with NEC. DLL3-targeting therapies are currently under clinical investigation, with promising antitumor activity demonstrated to date.

JWCAR-031: 一种DLL3调节剂药物，由Juno Therapeutics, Inc. (Juno Therapeutics, Inc.)公司最早进行研发，目前全球最高研发状态为临床前，作用机制: DLL3调节剂 (δ样蛋白-3调节剂)，治疗领域: 肿瘤,呼吸系统疾病，在研适应症: 小细胞肺癌，在研机构: Bristol Myers Squibb Co.,上海药明巨诺生物科技有限公司。

Dec 21, 2022 · The deal sees Juno grant licenses to patents and know-how in order to develop, manufacture, and commercialize a chimeric antigen receptor (CAR) T cell therapy targeting the solid tumor antigen DLL3 in the territory of Greater China.